Navigation Links
XELR8 Holdings Announces Continuation of 'XELR8 To A Million' Promotion
Date:7/2/2008

- Distributors Sales Success Prompts Extension of Promotion -

DENVER, July 2 /PRNewswire-FirstCall/ -- XELR8 Holdings, Inc. (Amex: BZI), a provider of functional foods, beverages and nutritional supplements, announced that "XELR8 To A Million" promotion attained a significant proportion of the $1 million sales goal for the month of June prompting management to offer distributors an opportunity to earn significant bonuses in July.

John Pougnet, CEO, noted, "Our distributors worked exceptionally hard during June and came close to attaining our ambitious goal of $1 million in sales in that month. We felt that such dedication and hard work should be rewarded even if the very aggressive sales goal was not reached. Consequently, we will be offering significant bonuses for sales leadership in July whereby distributors can earn large bonuses depending on their individual sales performance and ranking within the sales organization."

Toward the end of July, XELR8 will post the promotion's progress on its website: http://www.xelr8.com on the page/link marked "XELR8 Performs."

About XELR8 Holdings, Inc.

XELR8 Holdings, Inc. is a provider of nutritional foods and beverages designed to help enhance physical health and overall performance. XELR8 has developed a comprehensive line of nutritional supplements and functional foods designed in systems that are easy to take, simple to understand, and conveniently fit within a lifestyle. These include the Company's Eat/Drink/Snack System; Peak Performance System; and its newest market entry, Bazi(TM), a powerful, concentrated, antioxidant (Vitamins A, C & E) nutritional drink packed with eight different super fruits and berries, including the Chinese jujube plus 12 vitamins and 68 minerals, providing all the daily vitamins and minerals you need in a single, convenient, one-ounce shot.

XELR8's commitment to quality, science and research has earned the Company a loyal following of over 350 world-class athletes and an elite list of endorsers, such as 3-time World Series Champion Curt Schilling, five-time Cy Young Award Winner Randy Johnson; Super Bowl Champions Mike Alstott, Lawyer Milloy and Head Coach Mike Shanahan; professional football superstar Cadillac Williams; Olympians Briana Scurry and Caroline Lalive; Stanley Cup Winner Blake Sloan; and PGA Tour Professional Tom Pernice, Jr. XELR8 products are only available through independent distributors located throughout the nation. For more information about XELR8, please visit http://www.xelr8.com or http://www.drinkbazi.com

Contacts:

Stephen D. Axelrod, CFA

John Pougnet, CEO Alisa Steinberg (Media)

XELR8 Holdings, Inc. Wolfe Axelrod Weinberger Assoc. LLC

(303) 316-8577 (212) 370-4500

CEO@xelr8.com steve@wolfeaxelrod.com

alisa@wolfeaxelrod.com


'/>"/>
SOURCE XELR8 Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XELR8 Holdings Announces Record First Quarter Revenue
2. XELR8 Holdings Announces Fiscal 2007 Financial Results
3. XELR8 Holdings to Announce 2007 Third Quarter Results on Wednesday, October 31, 2007
4. Settlement Hearing for In Re PainCare Holdings, Inc. ("PRZ") Securities Litigation
5. American Healthcare Holdings Ranked in Top 100 HCIT Companies
6. Critical Homecare Solutions Holdings, Inc. Reports Full Year 2007 and First Quarter 2008 Results
7. Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program
8. NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share
9. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
10. HMS Holdings Corp. to Present at Jefferies 2nd Annual Healthcare Conference
11. HMS Holdings Corp. to Present at Stephens 2008 Spring Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: